Does Cigna Cover Wegovy?

Cigna's Coverage Policy for Wegovy

Cigna classifies Wegovy as a covered medication for chronic weight management under most of its commercial health plans, including PPO, HMO, and Open Access Plus products. Coverage is not automatic. Your prescriber must submit a prior authorization request, and Cigna's pharmacy benefit team reviews it against a defined set of clinical criteria before approving or denying the claim.

The FDA approved semaglutide 2.4 mg (Wegovy) in June 2021 for chronic weight management in adults with a body mass index (BMI) of 30 kg/m² or greater, or 27 kg/m² or greater with at least one weight-related comorbidity such as type 2 diabetes, hypertension, or dyslipidemia. Cigna's coverage criteria mirror these FDA label requirements closely, but add additional documentation hurdles. Plans administered through Cigna's employer-sponsored pharmacy benefit may have slightly different formulary placement than individual marketplace plans, so checking your specific Summary of Benefits and Coverage (SBC) document is a necessary first step.

Certain Cigna plans carved out through Express Scripts (Cigna's pharmacy benefit manager since 2018) may list Wegovy under a separate specialty pharmacy formulary. In those cases, the medication ships from a specialty pharmacy rather than being picked up at a retail location, and the copay structure follows specialty tier pricing. According to the Endocrine Society's 2024 Clinical Practice Guideline on pharmacological management of obesity, GLP-1 receptor agonists including semaglutide 2.4 mg represent first-line pharmacotherapy for patients meeting BMI thresholds who have not achieved target weight loss through lifestyle intervention alone [1].

What Formulary Tier Is Wegovy on Cigna?

Wegovy sits on Tier 4 or Tier 5 (non-preferred specialty) on most Cigna commercial formularies. That tier placement matters because it determines your out-of-pocket cost structure.

Tier 4 specialty drugs on Cigna plans typically carry a coinsurance of 25% to 33% rather than a flat copay. On a $1,349 monthly list price, 30% coinsurance translates to roughly $405 per fill before any manufacturer discount is applied. Some Cigna plans cap specialty drug out-of-pocket costs per fill at $150 to $250, but this cap varies by employer group. Tier 5 placement, when present, may carry even higher coinsurance or require use of a specific specialty pharmacy in Cigna's network.

The practical implication: even with Cigna coverage, your monthly cost for Wegovy could range from $0 (with a manufacturer savings card stacked on top of insurance) to $400 or more depending on your plan's benefit design. Patients who have already met their annual deductible will see lower per-fill costs. Those still accumulating toward the deductible may owe the full negotiated rate until the deductible threshold is crossed.

In the STEP-1 trial (N=1,961), semaglutide 2.4 mg produced a mean weight reduction of 14.9% from baseline at 68 weeks compared to 2.4% with placebo [2]. This degree of efficacy supports the cost-effectiveness argument that clinicians can use in PA requests and appeals when Cigna questions medical necessity.

Prior Authorization Criteria for Wegovy on Cigna

Cigna's prior authorization for Wegovy is classified as moderate difficulty. The PA will be approved more quickly if the submission packet includes every required element on the first attempt.

Cigna's standard PA criteria typically require documentation of all of the following:

1. BMI documentation. A recorded BMI of ≥30 kg/m², or ≥27 kg/m² with at least one weight-related comorbidity (hypertension, type 2 diabetes, dyslipidemia, or obstructive sleep apnea).

2. Lifestyle modification attempt. Evidence that the patient has participated in a structured diet and exercise program for at least 3 to 6 months. This can be documented through dietitian visit notes, physician-supervised weight management program records, or chart notes describing the intervention.

3. Step therapy completion (when required). Some Cigna plans require a documented trial and failure of at least one other anti-obesity medication before approving Wegovy. Commonly accepted prior agents include phentermine, phentermine-topiramate (Qsymia), naltrexone-bupropion (Contrave), or orlistat (Xenical/Alli).

4. Prescriber qualification. The prescribing clinician should be an MD, DO, NP, or PA. Some Cigna plans prefer that the prescriber be an endocrinologist, obesity medicine specialist, or primary care provider with documented weight management expertise.

5. No contraindicated conditions. The patient must not have a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2, consistent with the FDA-approved labeling [3].

PA approvals are typically granted for 6 to 12 months. Cigna may require re-authorization at renewal, often asking for documentation that the patient has achieved at least 5% body weight loss from baseline during the initial authorization period.

Does Cigna Require Step Therapy Before Wegovy?

Many Cigna commercial plans do enforce step therapy for Wegovy, though the specific requirements vary by employer group and plan design.

Step therapy, sometimes called "fail-first," means Cigna wants evidence that a less expensive anti-obesity medication was tried and either failed to produce adequate results or caused intolerable side effects before the plan will authorize Wegovy. The most commonly required first-step agent is phentermine, which costs between $10 and $30 per month and is approved for short-term use (up to 12 weeks by FDA labeling, though many clinicians prescribe it longer off-label).

A 2022 analysis published in Obesity found that step therapy requirements for GLP-1 receptor agonists delayed treatment initiation by a median of 4.2 months among commercially insured patients [4]. For patients with obesity-related comorbidities progressing during that delay period, clinicians can file a step therapy exception request. The exception request should include clinical documentation explaining why the required first-step agent is medically inappropriate for the specific patient. Valid reasons include prior adverse reactions, drug interactions, or contraindications.

Not all Cigna plans require step therapy. Self-funded employer plans (where the employer, not Cigna, makes formulary decisions) may waive step therapy entirely or substitute different criteria. Your plan's drug formulary document, available on myCigna.com, will specify whether step therapy applies.

How to Appeal a Cigna Denial of Wegovy

Cigna offers a two-level internal appeal process followed by an external review through an independent review organization (IRO). Knowing the structure upfront improves your odds.

Level 1 internal appeal. You or your prescriber must file within 180 days of the denial. The appeal is reviewed by a Cigna medical director who was not involved in the original denial decision. Include: the denial letter, a letter of medical necessity from the prescriber, relevant clinical trial data supporting semaglutide's efficacy (STEP-1 results are directly applicable here), documentation of prior weight loss attempts, and records of weight-related comorbidities. Cigna must respond within 30 days for a standard appeal or 72 hours for an expedited (urgent) appeal.

Level 2 internal appeal. If Level 1 is denied, you can request a second internal review. The same documentation standards apply, but this is an opportunity to add new clinical evidence or address specific reasons cited in the Level 1 denial.

External IRO review. After exhausting both internal levels, you have the right to an external review by an independent organization not affiliated with Cigna. The IRO reviewer is a board-certified physician, and their decision is binding on Cigna under the ACA's external review provisions. According to data from state insurance departments, external reviews overturn insurer denials approximately 40% to 60% of the time for specialty medications.

The American Association of Clinical Endocrinology (AACE) 2023 consensus statement recommends that insurers cover FDA-approved anti-obesity medications without excessive step therapy barriers, which provides additional supporting evidence for appeal letters [5]. Quoting guideline language directly in appeal correspondence can strengthen the medical necessity argument.

Using the Manufacturer Savings Card with Cigna

Novo Nordisk offers a savings card program for Wegovy that commercially insured patients, including those on Cigna plans, may use to reduce out-of-pocket costs. The card can bring the patient copay to as low as $0 per fill for eligible patients.

Eligibility requirements for the savings card include: the patient must have commercial insurance (not Medicare, Medicaid, or Tricare), the patient must have a valid Wegovy prescription, and the patient's insurance must cover Wegovy (the card reduces copay, not the total drug cost for uninsured patients, though Novo Nordisk has offered separate programs for cash-pay patients at various times).

The savings card works as a secondary payer. Cigna processes the claim first, determines the patient's copay or coinsurance amount, and then the savings card covers some or all of that remaining balance. The card has an annual maximum benefit, which Novo Nordisk adjusts periodically. Check the current terms at the Wegovy savings card page, as benefit levels and eligibility criteria change.

One important detail: if Cigna denies coverage for Wegovy, the manufacturer savings card will not cover the full list price. The card is designed to supplement insurance coverage, not replace it. Patients whose PA is denied should pursue the appeal process described above rather than relying solely on manufacturer assistance.

Cost Breakdown: Wegovy on Cigna Plans

The total out-of-pocket cost for Wegovy on a Cigna plan depends on several intersecting variables. Here is a realistic breakdown of what patients typically pay.

Before meeting the annual deductible, patients on a Tier 4 plan may owe the full negotiated rate, which can be close to or equal to the $1,349 list price. After the deductible, coinsurance of 25% to 33% applies, yielding a per-fill cost of $337 to $445. With the manufacturer savings card applied after insurance, many patients report paying $0 to $25 per month.

The dose escalation schedule during the first 16 weeks of Wegovy treatment uses lower-dose pens (0.25 mg, 0.5 mg, 1.0 mg, 1.7 mg) before reaching the maintenance dose of 2.4 mg. Each dose strength is priced the same at list price, so the monthly cost remains $1,349 regardless of dose level. Some Cigna plans apply the deductible separately to each fill, which means patients starting Wegovy early in their plan year may face several months of higher costs before the deductible is satisfied.

A 2023 Institute for Clinical and Economic Review (ICER) analysis estimated the cost-effectiveness threshold for semaglutide 2.4 mg at approximately $7,500 to $9,800 per quality-adjusted life year (QALY), well below the commonly accepted $50,000 to $150,000 per QALY willingness-to-pay threshold [6]. This data point is useful in appeal letters arguing that Wegovy coverage is cost-effective for the health plan.

What If Your Cigna Plan Excludes Anti-Obesity Medications?

Some Cigna employer-sponsored plans contain a blanket exclusion for anti-obesity medications. This exclusion removes the entire drug class from coverage, meaning no PA submission will result in approval.

If your plan has this exclusion, your options include:

Open enrollment change. If your employer offers multiple Cigna plan options, check whether a different plan tier covers anti-obesity medications. The higher-premium plan may include drug classes that the lower-premium plan excludes.

Employer advocacy. HR departments can request that Cigna add anti-obesity medication coverage to the plan's formulary during the annual renewal negotiation. Providing your HR team with cost-effectiveness data and clinical evidence may support this request.

Manufacturer patient assistance. Novo Nordisk operates patient assistance programs for patients without coverage. Eligibility is typically income-based.

Alternative FDA-approved indication. Semaglutide is also approved at a different dose (Ozempic, 0.5 mg to 2.0 mg) for type 2 diabetes. If the patient has a concurrent type 2 diabetes diagnosis, the prescriber may consider Ozempic instead, which is more commonly covered on Cigna formularies because diabetes medications face fewer exclusion barriers. This is a clinical decision that must be made between the patient and prescriber based on the individual's full medical picture.

The SELECT cardiovascular outcomes trial (N=17,604) demonstrated that semaglutide 2.4 mg reduced major adverse cardiovascular events by 20% in adults with overweight or obesity and established cardiovascular disease [7]. Dr. A. Michael Lincoff, the trial's lead investigator, stated: "These findings establish that treating obesity with semaglutide reduces cardiovascular risk independent of diabetes status." This cardiovascular benefit data has prompted some insurers to reconsider exclusions for anti-obesity medications, and it may strengthen appeals where cardiovascular risk reduction is clinically relevant.

Timeline: From Prescription to First Injection on Cigna

Understanding the typical timeline helps set realistic expectations.

Day 1. Prescriber submits the prior authorization request to Cigna, including all required clinical documentation.

Days 2 to 5. Cigna's pharmacy utilization management team reviews the PA. Standard turnaround is 5 business days; urgent/expedited review is 24 to 72 hours.

Day 5 to 7. If approved, the prescription is routed to a Cigna-contracted specialty pharmacy or retail pharmacy. Specialty pharmacies typically require a welcome call with the patient before dispensing.

Day 7 to 14. Medication is shipped (specialty pharmacy) or filled for pickup (retail pharmacy). The patient completes any required copay processing, including applying the manufacturer savings card.

If the PA is denied, the timeline extends. A Level 1 appeal adds up to 30 days, and a Level 2 appeal adds another 30 days. Expedited appeals may compress this. Patients whose clinical situation is urgent (e.g., BMI ≥40 with uncontrolled comorbidities) should have their prescriber request an expedited review at every stage.

The first injection uses the 0.25 mg dose, administered subcutaneously once weekly. The STEP-1 protocol escalated the dose every 4 weeks: 0.25 mg for weeks 1 to 4, 0.5 mg for weeks 5 to 8, 1.0 mg for weeks 9 to 12, 1.7 mg for weeks 13 to 16, and 2.4 mg from week 17 onward [2].